Editing Pfizer (section)

==Impact of US Administration-Imposed Tariffs on Pfizer==

Per [[Yahoo Finance]], Pfizer maintains a wide economic moat supported by steady cash flows and a diversified portfolio of patent-protected drugs, along with scale advantages in research and development.<ref>{{cite web |last=Karr |first=Bob |title=Pfizer Inc. (PFE): Why Are Street Analysts Bullish On This Wide Moat Stock Now? |url=https://finance.yahoo.com/news/pfizer-inc-pfe-why-street-071938162.html |website=Yahoo Finance |date=September 24, 2024 |access-date=April 10, 2025}}</ref>

As several media outlets note, Pfizer's role in global healthcare provides it with some insulation from international tariff disputes, as pharmaceutical products are generally exempt from tariffs under international trade agreements and governmental trade policies.<ref>{{cite news |last=Robbins |first=Rebecca |title=Trump’s Next Tariffs Target Could Be Foreign-Made Medicines |url=https://www.nytimes.com/2025/04/04/health/drug-tariffs-trump-manufacturing.html |work=The New York Times |date=2025-04-04 |access-date=2025-04-09}}</ref><ref>{{cite web |last=Bratulic |first=Anna |title=Drugmakers scramble to decode true impact of Trump's new tariff plan |url=https://firstwordpharma.com/story/5947155 |website=FirstWord Pharma |date=2025-04-02 |access-date=2025-04-09}}</ref><ref>{{cite web |last=Gatlin |first=Allison |title=Is Pfizer Stock A Sell As HHS Firings, Tariffs Cast A Pall On Pharma? |url=https://www.investors.com/news/technology/pfizer-stock-buy-now/ |website=Investor's Business Daily |date=2025-04-04 |access-date=2025-04-09}}</ref> Per ''[[The Wall Street Journal]]'', Health Care Industry and Consumer staples are among the least impacted.<ref>{{cite news |last1=Heeb |first1=Gina |last2=Gottfried |first2=Miriam |last3=Gallagher |first3=Dan |title=The Big Losers in Trump’s Tariff Chaos—and a Couple of Survivors |url=https://www.wsj.com/finance/stocks/the-big-losers-in-trumps-tariff-chaosand-a-couple-of-survivors-374730fc |work=The Wall Street Journal |date=2025-04-04 |access-date=2025-04-09}}</ref> In February 2025, Pfizer’s CEO Albert Bourla emphasized the company’s ability to mitigate potential future tariffs by shifting manufacturing to its 13 U.S. facilities, including large-scale sites dedicated to sterile injectables and antibody production.<ref>{{cite news |last=Nix |first=Jessica |title=Pfizer Vulnerable to Threat of European Tariffs, CEO Says |url=https://www.bloomberg.com/news/articles/2025-02-18/pfizer-vulnerable-to-threat-of-european-tariffs-ceo-bourla-says |work=Bloomberg News |date=February 18, 2025 |access-date=April 10, 2025}}</ref>

[[Donald Trump]] said in February 2025 that he was considering four exemptions to reciprocal tariffs, including pharmaceutical industries.<ref>{{cite news |last=Santhosh |first=Christy |title=Pfizer could use existing US manufacturing to counter potential tariff hit |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-could-move-outside-manufacturing-us-says-ceo-2025-03-03/ |work=Reuters |date=2025-03-04 |access-date=2025-04-09}}</ref>